Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
基本信息
- 批准号:10448406
- 负责人:
- 金额:$ 64.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-17 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAgonistAnimalsAntifungal AgentsAntigensBindingBlastomycesC Type Lectin ReceptorsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCellsCombined VaccinesCommunicable DiseasesDevelopmentDinucleoside PhosphatesFosteringFungal VaccinesGenetic TranscriptionGoalsHumanImmunityImmunizationImmunologic ReceptorsImmunologistInfluenza A virusInhalationInterleukin-2LigandsLipid ALungMaintenanceMemoryMucous MembraneMycosesPPBP genePathway interactionsPeriodicityPolysaccharidesPrimary InfectionPublic HealthReportingResidenciesRespiratory SystemRespiratory Tract InfectionsStructure of parenchyma of lungSystemT cell responseT memory cellT-LymphocyteTLR4 geneTestingTh1 CellsTimeTissuesVaccine AdjuvantVaccinesViralViral Respiratory Tract InfectionVirusWorkbasebeta-Glucansdectin 1designfactor Cfunctional plasticityfungal pneumoniafungushuman pathogeninfluenza A virus nucleoproteininfluenzavirusinnovationinsightmemory CD4 T lymphocytemouse dectin-2nanoemulsionparenteral administrationparticlepathogenpathogenic funguspathogenic microbepathogenic virusprogramsrespiratorysingle-cell RNA sequencingsoundstem cellsstem-like cellstemnesstooltranscription factortranscriptomevaccine developmentvaccine formulation
项目摘要
ABSTRACT: Respiratory infections with viruses and fungi constitute major public health problems globally.
Except for influenza virus, there are no licensed vaccines against viruses or fungi. It is generally agreed that
induction of T-cell memory is critical for defense against viruses and fungi in the respiratory tract. We and others
have shown that induction of tissue-resident memory (TRM) CD8 and CD4 T cells and systemic migratory memory
CD4 T cells are essential for protection against influenza A virus (IAV) and inhaled fungi, respectively. However,
both TRM cells and systemic memory CD4 T cells undergo attrition, leading to short-lived immunity, which is
especially true for TC1/TH1 cells. Therefore, induction of durable T-cell immunity poses major challenges for
vaccinologists. As compared to TH1 cells, TH17 cells display sought-after attributes of stem-ness, durability and
functional plasticity. We propose to tailor combination adjuvants to harness T17 programming and induce durable
and protective lung TRM cells and migratory memory CD4 T cells against viruses and fungi.
We find that Adjuplex, a nano-emulsion adjuvant, when combined with the TLR4 agonist glucopyranosyl
lipid A (GLA), evokes antigen-specific CD8 and CD4 T-cell responses in the lung that are: (i) durable and
multifaceted (TC1/TC17/TH1/TH17), and (ii) confer heterosubtypic immunity against IAV that persists >400 days.
We further find that combining those adjuvants with fungal CLR ligands Blastomyces endoglucanase 2 (Bl-Eng2;
Dectin-2 agonist) and b-glucan particles (Dectin-1 agonist) augments antiviral TC17/TH17/TC1/TH1 and elicits
migratory memory T cells that protect against fungal pneumonia. By single-cell RNAseq, we found that our
combined adjuvants induce memory antiviral and antifungal CD8 and CD4 T-cell clusters that express ICOS
(Inducible T Cell Co-stimulator), the transcription factor c-Maf, and a transcriptome that fosters tissue residency,
stem cell-ness and non-pathogenic T17 programming. Cyclic dinucleotides also promote T17 programming in
lungs. This, we postulate that programming stem cell-like, functionally plastic, non-pathogenic TC17/TH17
memory cells with our combination adjuvants (that engage TLR-4, Dectin-1/2 and STING pathways) will foster
durable protective immunity to viral and fungal pathogens in the lung. Our specific aims will test three
hypotheses: Aim 1: Combination adjuvants that evoke TC17/TH17 stem cell-like functionally-plastic TRM or
systemic migratory memory will engender durable immunity to respiratory viral and fungal pathogens; Aim 2:
Functional plasticity of TC17/TH17 memory is important for protective immunity to viruses and fungi; Aim 3: The
ICOS/c-Maf pathway is integral to establishment and/or maintenance of durable vaccine-induced protective
immunity to respiratory viral and fungal infections. The proposed work is significant and of high impact because
it has the potential to create a tractable adjuvant system/tool kit that will advance the formulation of vaccines: (i)
targeted for mucosal or parenteral administration; (ii) designed to induce TRM or systemic T-cell memory; and (iii)
tailored to elicit CD8 and CD4 T cells that protect against diverse pathogens such as viruses and fungi.
摘要:病毒和真菌引起的呼吸道感染是全球主要的公共卫生问题。
除流感病毒外,目前还没有针对病毒或真菌的许可疫苗。人们普遍认为
T细胞记忆的诱导对于防御呼吸道中的病毒和真菌是至关重要的。我们和其他人
已经表明,诱导组织驻留记忆(TRM)CD 8和CD 4 T细胞和系统迁移记忆
CD 4 T细胞分别对预防甲型流感病毒(IAV)和吸入性真菌至关重要。然而,在这方面,
TRM细胞和系统记忆性CD 4 T细胞都经历了磨损,导致短暂的免疫,
尤其是对于TC 1/TH 1细胞。因此,诱导持久的T细胞免疫对免疫系统构成了重大挑战。
疫苗学家与TH 1细胞相比,TH 17细胞显示出干细胞性、耐久性和细胞周期性的受欢迎属性。
功能可塑性我们建议定制组合佐剂以利用T17编程并诱导持久的免疫应答。
以及保护肺TRM细胞和迁移记忆CD 4 T细胞对抗病毒和真菌。
我们发现,Adjuplex,一种纳米乳剂佐剂,当与TLR 4激动剂吡喃葡萄糖结合时,
脂质A(GLA)在肺中引起抗原特异性CD 8和CD 4 T细胞应答,所述应答是:(i)持久的,
多方面的(TC 1/TC 17/TH 1/TH 17),和(ii)赋予针对IAV的持续>400天的异亚型免疫。
我们进一步发现,将这些佐剂与真菌的β-葡聚糖配体芽生菌内切葡聚糖酶2(Bl-Eng 2;
Dectin-2激动剂)和β-葡聚糖颗粒(Dectin-1激动剂)增强抗病毒TC 17/TH 17/TC 1/TH 1和抗肿瘤活性
迁移性记忆T细胞可以预防真菌性肺炎。通过单细胞RNAseq,我们发现,
联合佐剂诱导表达ICOS的记忆性抗病毒和抗真菌CD 8和CD 4 T细胞簇
(可诱导的T细胞共刺激分子)、转录因子c-Maf和促进组织驻留的转录组,
干细胞性和非致病性T17编程。环状二核苷酸也促进T17编程,
肺因此,我们假设编程性干细胞样、功能可塑性、非致病性TC 17/TH 17
使用我们的组合佐剂(参与TLR-4,Dectin-1/2和STING途径)的记忆细胞将促进
对肺部病毒和真菌病原体的持久保护性免疫。我们的具体目标将测试三个
假设:目的1:诱发TC 17/TH 17干细胞样功能可塑性TRM或
系统迁移记忆将产生对呼吸道病毒和真菌病原体持久免疫力;目标2:
TC 17/TH 17记忆的功能可塑性对于针对病毒和真菌的保护性免疫是重要的;
ICOS/c-Maf途径是建立和/或维持持久疫苗诱导的保护性免疫应答的必要条件。
对呼吸道病毒和真菌感染的免疫力。拟议的工作意义重大,影响深远,因为
它有可能创造一个易于处理的佐剂系统/工具包,将促进疫苗的配制:
靶向粘膜或肠胃外给药;(ii)设计用于诱导TRM或全身性T细胞记忆;和(iii)
定制以引发CD 8和CD 4 T细胞,以保护免受病毒和真菌等多种病原体的侵害。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRUCE Steven KLEIN其他文献
BRUCE Steven KLEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRUCE Steven KLEIN', 18)}}的其他基金
Mechanisms of vaccine immunity against coccidioidomycosis
球孢子菌病疫苗免疫机制
- 批准号:
10584260 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
Mechanisms of Vaccine Immunity against Coccidioidomycosis
球孢子菌病疫苗免疫机制
- 批准号:
10591641 - 财政年份:2022
- 资助金额:
$ 64.75万 - 项目类别:
Lung epithelial cell regulation of immunity to inhaled fungi
肺上皮细胞对吸入真菌免疫的调节
- 批准号:
10222492 - 财政年份:2018
- 资助金额:
$ 64.75万 - 项目类别:
Lung epithelial cell regulation of immunity to inhaled fungi
肺上皮细胞对吸入真菌免疫的调节
- 批准号:
10451274 - 财政年份:2018
- 资助金额:
$ 64.75万 - 项目类别:
Lung epithelial cell regulation of immunity to inhaled fungi
肺上皮细胞对吸入真菌免疫的调节
- 批准号:
9975090 - 财政年份:2018
- 资助金额:
$ 64.75万 - 项目类别:
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
- 批准号:
10614603 - 财政年份:2016
- 资助金额:
$ 64.75万 - 项目类别:
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
- 批准号:
10224468 - 财政年份:2016
- 资助金额:
$ 64.75万 - 项目类别:
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
组合佐剂可对呼吸道病毒和真菌病原体产生持久免疫
- 批准号:
10544356 - 财政年份:2016
- 资助金额:
$ 64.75万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 64.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 64.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 64.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)